doi: 10.4149/gpb_2020026

Short Communication

CD44 and vimentin, markers involved with epithelial-mesenchymal transition: A proteomic analysis of sequential proteins extraction of triple-negative breast cancer cells after treatment with all-*trans* retinoic acid

Dana Strouhalova¹, Dana Macejova², Marketa Lastovickova¹, Julius Brtko² and Janette Bobalova¹

¹ Institute of Analytical Chemistry of the CAS, Brno, Czech Republic

² Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia

Abstract. This work aimed to provide, in one isolation and separation step, an overview of the content of proteins with different solubility after treatment with all-*trans* retinoic acid, which is considered to be an important therapeutic agent, predominantly in acute promyelocytic leukemia. Breast, ovarian, bladder, and skin cancers have been demonstrated to be suppressed by retinoic acid, as well. The bottom-up proteomic strategies were applied for the analysis of proteins extracted from triple-negative breast cancer MDA-MB-231 cells utilizing a commercially manufactured kit. The gel electrophoresis followed by MALDI-TOF MS analysis was used for protein determination. By employing PDQuest[™] software, we identified several proteins affected by all-*trans* retinoic acid. Two proteins, vimentin and CD44, which are associated with the epithelial-mesenchymal transition, were selected for a detailed study. We have found that all-*trans* retinoic acid results in significantly reduced levels of vimentin and CD44, where protein level in the cytoplasmic fraction was almost completely suppressed.

Key words: Breast cancer — All-*trans* retinoic acid — Proteins — Biomarker — Sequential protein extraction

The knowledge of the structure, function, and amount of specific proteins associated with the epithelial-mesenchymal transition (EMT) process is essential for the development of effective diagnostic approaches to breast cancer with the perspective of diagnosing and treating malignancies (Neagu et al. 2019). EMT is characterized by the downregulation of epithelial markers and the upregulation of the mesenchymal markers. Of the known breast cancer markers, attention has been drawn to vimentin (VIME), which is a marker of the mesenchymal phenotype (Satelli and Li 2011) as well as CD44, which is a transmembrane glycoprotein of which expression is associated with resistance to therapy and poorer prognosis of many cancers (Ahrens et al. 2001; Li et al. 2007). Both proteins are expressed in a large number of

variants resulting from their posttranslational modifications (phosphorylation, glycosylation, glycosaminoglycanation). Because alternative splicing and posttranslational modifications generate many different sequences, including, perhaps, tumor-specific sequences, the production of anti-tumorspecific agents may be a realistic therapeutic approach (Eibl et al. 1995).

CD44 overexpression is a characteristic marker for tumorigenic cancer cells (TCC) population of breast cancer (Al-Hajj et al. 2003), colon (Dalerba et al. 2007), pancreas (Li et al. 2007) and prostate (Collins et al. 2005). To date, a number of other TCC markers have been described that are associated with tumorigenicity, strain, apoptosis, and invasiveness. In many cancers, high levels of CD44 expression are not always associated with adverse outcomes (Chen et al. 2018). Current findings have shown that different variants of CD44 are expressed in human tumors and the prognosis can be estimated according to the type of isoform. Various

Correspondence to: Janette Bobalova, Institute of Analytical Chemistry of the CAS, Veveří 97, 602 00 Brno, Czech Republic E-mail: bobalova@iach.cz

research groups analyzing the same neoplastic disease came to conflicting conclusions about the correlation between CD44 expression and disease prognosis, probably due to differences in methodology (Eibl et al. 1995; Naor et al. 2002). These problems need to be solved and further studies are needed to determine the prognostic value of CD44 and its variant isoforms.

MDA-MB-231, a triple-negative breast cancer model, was used in this study to evaluate and compare membrane and cytoplasmic proteins after retinoic acid isomer treatment. Proteins were extracted using a commercially available kit, separated on SDS-PAGE, and characterized by MALDI-TOF/TOF MS/MS.

The cancer cell culture was purchased from the HPACC (Salisbury, Great Britain). Cells were grown and passaged routinely as monolayer culture. For experiments, the cells were seeded into Petri dishes (6 cm diameter, TPP, Switzerland) at 1.2×10^6 cells/dish density in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), antibiotics (penicillin, streptomycin, gentamicin) and treated for 48 h with 1 µmol/l all-trans retinoic acid (ATRA) in a humidified atmosphere of 5% CO₂ and 95% air at 37°C. A stock solution of ATRA was originally dissolved in ethanol, and an equal volume of ethanol (final concentration < 0.02%) was added to the control cells. Then cells were washed twice with ice-cooled PBS. The sequential protein extraction was made according to an instruction manual of ReadyPrep[™] Protein Extraction Kit Bio Rad.

Proteomic analysis of membrane proteins is challenged by the protein solubility and detergent incompatibility with MS analysis. Here, we used the ReadyPrep protein extraction kit which is a simple, rapid, and reproducible method to prepare protein fractions highly enriched in the membrane and cytoplasmic proteins. This approach makes it possible to reduce the complexity of the sample in order to improve the chances of identifying low-occurring proteins and to simplify proteomic studies. The advantage of this procedure is that the kit does not require the use of ultracentrifugation which is commonly used for these purposes. The fractionation protocol used in this work involved a separation of membrane proteins using Triton X-114 detergent (Bordier 1981; Santoni et al. 2000a, 2000b). The sample was homogenized in the membrane protein extraction buffers and incubated at 37°C and centrifuged. The resulting sample was divided into two phases, an upper aqueous phase (cytoplasmic) and a lower detergent-rich phase (membrane). Both protein fractions, hydrophobic and hydrophilic parts, were purified using the ReadyPrep[™] 2-D Cleanup Kit by Bio-Rad for further analyses and gel electrophoresis separation. The purification procedure resulted in quantitative precipitation and protein concentration in the sample while reducing the amount of salts and other substances from the isolation procedure. The final protein pellets after each precipitation step were dissolved in a Laemmli sample buffer and ready for use in gel electrophoresis. After briefly being boiled (10 min, 95°C) in a water bath, samples were applied onto the 12% SDS gel. Separations were performed at constant voltage 140 V. The visualization was carried out using Coomassie Brilliant Blue G-250 dye. Stained protein bands were excised from the gel and digested (after reduction with 10 mM dithiothreitol and subsequent alkylation with 55 mM iodoacetamide) with trypsin (digestion buffer: 50 mM NH₄HCO₃, 5 mM CaCl₂, 12.5 ng/µl of enzyme) overnight at 37°C. The resulting tryptic peptides were extracted from the gel by 0.1% trifluoroacetic acid (TFA) and acetonitrile (1:1, v/v). For mass spectrometric analyses, the extracts were purified by ZipTip C₁₈ (Millipore). A solution of a-cyano-4-hydroxycinnamic acid (10 mg/ml in acetonitrile/0.1% TFA, 1:1, v/v) was used for both MS and MS/MS analysis of peptides. MALDI MS experiments in positive ion reflectron mode were performed on AB SCIEX TOF/TOF™ 5800 System (AB SCIEX, Framingham, MA, USA) equipped with a 1 kHz Nd:YAG laser. Acquired mass spectra were processed using 4000 Series Explorer software and the data were submitted to the Mascot database searching. Protein identifications were assigned using the SwissProt database with taxonomy restriction to Homo sapiens. Maximum tolerance for peptide masses, as well as fragment error, was set to 0.6 Da. Additional parameters used: enzyme trypsin; allowed missed cleavages: up to one, fixed modification: carbamidomethyl, no variable modification; peptide charge: +1; monoisotopic masses; instrument MALDI-TOF/TOF.

In this work, we analyzed and compared the protein profiles of the membrane and cytoplasmic fractions of MDA-MB-231 cells after treatment with ATRA.

Our previous studies have shown that the natural retinoid ATRA, a cognate ligand of nuclear retinoic acid receptors (RARs), is a promising agent that affects the proteomic profile of cancer cells (Flodrova et al. 2015, 2017). ATRA belongs to a class of retinoids that are known to have a wide range of functions (Alizadeh et al. 2014). Breast, lung, prostate, ovarian, bladder, and skin cancers have been demonstrated to be suppressed by ATRA (Chen et al. 2014). ATRA is known for several decades for its therapeutic effects due to antiproliferative and apoptosis-inducing action, and thus to act in the treatment or prevention of cancer (Carlberg et al. 1993). Furthermore, they inhibit carcinogenesis and suppress tumour growth and invasion in various tissues (Shi et al. 2019), which was the main reason, why ATRA has been used in our studies. The presented study consists of several aims: i) to perform a basic comparison of the membrane and cytoplasmic fractions of MDA-MB-231 cells based on SDS-gels protein profiles; *ii*) to identify the major proteins related to EMT; iii) to quantify VIME and CD44 after treatment of ATRA.

First, we compared the membrane and cytoplasmic fractions of both control cells and cells after treatment. Figure 1A shows the protein profiles of the non-treated (control) fractions. Visual inspection of the protein pattern indicated that the membrane and the cytoplasmic fraction share some similarities. On the other hand, significant differences in the electrophoretic profiles of both fractions were observed at molecular weights of approximately 30–50 kDa (Fig. 1A, B). In addition, considerable changes between fractions after treatment in the higher molecular masses (80–110 kDa) were observed (Fig. 1B). The bands showing differences between fractions were cut off and used for further proteomic evaluation including gel tryptic digestion, MALDI-TOF MS. Additional MS/MS analysis of individual peptides and following database searching resulted in the identification of the proteins summarized in Table 1 and Table 2. Selected important proteins are indicated on the SDS gels and are also listed in bold in the tables.

Among proteins with regard to EMT, of importance are predominantly VIME and CD44. As expected, these wellknown human breast cancer markers were identified in mass area about 55 kDa (VIME) and about 85 kDa (CD44) in our experiment. In addition, a high molecular weight form of VIME (VIME HMW) has also been identified, the occur-




Figure 1. SDS-PAGE separation of the membrane and cytoplasmic proteins of MDA-MB-231 cells. **A.** Non-treated sample (control sample). **B.** Sample after 48-h treatment with ATRA. The bands showing differences between fractions were cut off and used for further proteomic evaluation including gel tryptic digestion, MALDI-TOF MS. Selected important proteins are listed on the SDS gel and are shown in bold in the tables. MW, molecular weight.

ц
tion
g
fr
Ħ
ce
al
qn
ivid
.ш
e in inc
le
<u>p</u> _
ar
ated sam
te
ea
÷,
ģ
nc
ound in non-treat
р
E
fo
JS
eii
ot
pr
pa
iffe
nti
de
fic
Ö
ury
na
IU
ŝu
s.
e 1
Iable
Tal
£ .

OIT OIT ABAccessionMass (Da)ABKIZIB_HUMAN184316ABKIZIB_HUMAN184316ABKIZIB_HUMAN184316ABKIZIB_HUMAN2696ABSPPQ_HUMAN75216BPP_HUMAN8200157PQ_HUMANABSPPQ_HUMAN7320Abperone BiPBIP_HUMAN7320Abperone BiPBIP_HUMAN7320Abperone BiPBIP_HUMAN7326Abperone BiPBIP_HUMAN7326Abperone BiPBIP_HUMAN7302Abperone BiPBIP_HUMAN7302Abperone BiPBIP_HUMAN5625Abperone BiPHOMAN5020Abperone BiPBIP_HUMAN5026Abperone BiPBIP_HUMAN33707BiPBIP_HUMAN33707BiPBIPBIPAbperone BiPBIPAbperoneBiPBIPBIP2010 <td< th=""><th></th><th></th><th></th><th>MEMORANE ER ACTION</th><th></th><th>1. Contraction of the second s</th><th></th></td<>				MEMORANE ER ACTION		1. Contraction of the second s	
Accession Mass(Da) KI21B_HUMAN 184316 ARHG1_HUMAN 184316 ARHG1_HUMAN 13056 ENPL_HUMAN 25696 ENPL_HUMAN 76216 GRP75_HUMAN 76216 SFPQ_HUMAN 76216 GRP75_HUMAN 76216 BIP_HUMAN 76216 GRP75_HUMAN 76216 FSP7C_HUMAN 76216 GRP75_HUMAN 76216 FSP7C_HUMAN 73920 BIP_HUMAN 73920 KICL0_HUMAN 76216 MDEL_HUMAN 73920 ROA1_HUMAN 66170 CH60_HUMAN 55020 ATPB_HUMAN 55020 ATPB_HUMAN 55020 ATPB_HUMAN 55020 MPCP_HUMAN 55020 MPCP_HUMAN 33576 NMPL_HUMAN 33576 NMPLM_HUMAN 33576 NMPLM_HUMAN 33576 NMPLM_HUMAN 33576 NPM_HUMAN 33707				MEMBRANE FRACTION		CI	I UPLASMIC FRACTION
KI21IB_HUMAN 184316 ARHGI_HUMAN 26696 ENPIL_HUMAN 22696 ENPIL_HUMAN 22696 ENPIL_HUMAN 22601 SFPQ_HUMAN 76216 GRP75_HUMAN 76216 SFPQ_HUMAN 76216 SFPQ_HUMAN 76216 BIP_HUMAN 76216 GRP75_HUMAN 76216 BIP_HUMAN 73920 BIP_HUMAN 73920 BIP_HUMAN 73920 BIP_HUMAN 73920 BIP_HUMAN 73920 BIP_HUMAN 73920 BIP_HUMAN 73020 BIP_HUMAN 5625 HOBB3_HUMAN 5625 VIME_HUMAN 5652 VIME_HUMAN 5652 VIME_HUMAN 38358 MPCP_HUMAN 333707 MPCP_HUMAN 333576 MPHM_HUMAN 333576 NMPHM_HUMAN 33576 NMPHM_HUMAN 33376 MDHM_HUMAN 33376 NPM_M_HUMAN 33376 NPM_M_HUMAN 33376		Accession	Mass (Da)	Description	Accession	Mass (Da)	Description
ARHGI_HUMAN 103056 ENPL_HUMAN 22696 ENPL_HUMAN 76216 SFPQ_HUMAN 76216 GRP75_HUMAN 75216 GRP75_HUMAN 75216 GRP75_HUMAN 75216 FPQ_HUMAN 75216 GRP75_HUMAN 75200 BIP_HUMAN 73920 BIP_HUMAN 73920 BIP_HUMAN 73920 BIP_HUMAN 73920 BIP_HUMAN 73920 BIP_HUMAN 73920 CGLLLHUMAN 66170 CH60_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 5937 NPCP_HUMAN 333576 NPCP_HUMAN 333576 NPME_HUMAN 33576 NPME_HUMAN 33576 NPME_HUMAN 33576 NPME_HUMAN 33576 NPME_NAUMAN 33766 NPM_M_HUMAN 33776		TASO2_HUMAN	271697	Protein TASOR 2	KI21B_HUMAN	184316	Kinesin-like protein KIF21B
ENPL_HUMAN 25696 RPP2_HUMAN 76216 SFPQ_HUMAN 76216 GRP75_HUMAN 75216 GRP75_HUMAN 75216 GRP75_HUMAN 75216 BIP_HUMAN 75216 GRP75_HUMAN 75216 BIP_HUMAN 75920 BIP_HUMAN 73920 BIP_HUMAN 73920 KGRP7_HUMAN 73920 KZCL_HUMAN 66170 CH60_HUMAN 66170 KZCL_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 5937 NMPCP_HUMAN 38358 NMPCP_HUMAN 38357 NMPL_HUMAN 33707 Joig NPM_HUMAN 33707 NDHM_HUMAN 33707 State 33376 NPM_HUMAN 33707 State 33707 State 337464 <t< td=""><td></td><td>ITA2_HUMAN</td><td>130468</td><td>Integrin alpha-2</td><td>ARHG1_HUMAN</td><td>103056</td><td>Rho guanine nucleotide exchange factor 1</td></t<>		ITA2_HUMAN	130468	Integrin alpha-2	ARHG1_HUMAN	103056	Rho guanine nucleotide exchange factor 1
CD44_HUMAN 82001 SFPQ_HUMAN 76216 GRP75_HUMAN 76216 BIP_HUMAN 73920 BIP_HUMAN 66170 CALX_HUMAN 66170 KICL0_HUMAN 66170 KICL0_HUMAN 59020 ATPB_HUMAN 50788 NMPCP_HUMAN 50788 NMPCP_HUMAN 50525 VIME_HUMAN 50525 VIME_HUMAN 33356 MPPA_HUMAN 33576 MPPA_HUMAN 33576 NMPLM_HUMAN 33576 NMPLM_HUMAN 33576 NMPLM_HUMAN 33576 NMPLM_HUMAN 33576 NMPLM_HUMAN 33576 NPM_MAN 33776 Solo NPM_MAN Solo NPM_MAN So		SMCA1_HUMAN	123211	Probable global transcription activator SNF2L1	ENPL_HUMAN	92696	Endoplasmin
SFPQ_HUMAN 76216 BIP_HUMAN 73920 BIP_HUMAN 73920 BIP_HUMAN 73920 BIP_HUMAN 73920 HSP7C_HUMAN 73920 HSP7C_HUMAN 68624 CALX_HUMAN 68624 CALX_HUMAN 66170 KZCL_HUMAN 66170 KIC10_HUMAN 59020 ATPB_HUMAN 50788 NMPCP_HUMAN 50788 NMPL_HUMAN 50525 VIME_HUMAN 50788 MPCP_HUMAN 50788 NMPL_HUMAN 335676 TBAIA_HUMAN 33576 NMPCP_HUMAN 33576 MPROL_HUMAN 33576 NMPL_HUMAN 33576 NMPLM_HUMAN 33576 NMPLM_HUMAN 33576 NPM_HUMAN 33576 NPM_HUMAN 33576 Solo NPM_HUMAN 33576 Solo NPM_HUMAN 32726 Solo NPM_HUMAN 32726 Solo NPM_HUMAN 32726 Solo N	.I		107263	Neutral alpha-glucosidase AB	CD44_HUMAN	82001	CD44 antigen
GRP75_HUMAN 73920 BIP_HUMAN 73920 HSP7C_HUMAN 73920 HSP7C_HUMAN 73920 HSP7C_HUMAN 73920 HSP7C_HUMAN 68624 CALX_HUMAN 68624 KZCL_HUMAN 66170 KTCI0_HUMAN 66170 KTCI0_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 50020 MPCP_HUMAN 50788 MPCP_HUMAN 50788 MPCP_HUMAN 53676 TBAIA_HUMAN 50788 MPCP_HUMAN 33576 NPME_HUMAN 35358 NPCP_HUMAN 35356 NPM_MAN 35707 Sood 33358 NDHM_HUMAN 35707 Sood NDHMAN 35726 NPM_HUMAN 35707 Sood NPM_HUMAN 35726 Sood NPM_HUMAN 35726 Sood NPM_HUMAN 35726 Sood NPM_HUMAN 35726<	uo		91664	Integrin beta-1	SFPQ_HUMAN	76216	Splicing factor, proline- and glutamine-rich
BIP_HUMAN 72402 HSP7C_HUMAN 72402 HSP7C_HUMAN 68624 HSP7C_HUMAN 68624 FXCI_HUMAN 68624 KZCI_HUMAN 66170 KZCI_HUMAN 66170 KTCI0_HUMAN 66170 MPP_HUMAN 59020 ATPB_HUMAN 55525 VIME_HUMAN 55026 NPCP_HUMAN 55020 MPCP_HUMAN 55020 MPCP_HUMAN 55020 MPCP_HUMAN 35358 MPCP_HUMAN 35358 NPM_HUMAN 35358 NPCP_HUMAN 35707 BOA1_HUMAN 35537 NDHM_HUMAN 35707 Strand 33707 BOA1_HUMAN 35707 CIQBP_HUMAN 35707 Strand 33707 BOB NPM_HUMAN 35726 Strand NPM_HUMAN 35726 Strand NPM_HUMAN 35726 Strand Strand 377464	igə		82001	CD44 antigen	GRP75_HUMAN	73920	Stress-70 protein, mitochondrial
HSP7C_HUMAN 71082 H90B3_HUMAN 68624 H90B3_HUMAN 68624 K2C1_HUMAN 66170 K2C1_HUMAN 66170 KTCI0_HUMAN 66170 KTCI0_HUMAN 59020 ATPB_HUMAN 59020 MPCP_HUMAN 59020 ATPB_HUMAN 55525 VIME_HUMAN 50503 MPCP_HUMAN 36761 TBAIA_HUMAN 50503 MPCP_HUMAN 38337 NPCP_HUMAN 33507 MPCP_HUMAN 33507 Jog NDHM_HUMAN 33507 Job NPM_HUMAN 33507 Job NPM_HUMAN 33707 Stssp_HUMAN 35726 Stssp_HUMAN 357464 Stssp_HUMAN 35	Я		73920	Stress-70 protein, mitochondrial	BIP_HUMAN	72402	Endoplasmic reticulum chaperone BiP
H90B3_HUMAN 68624 CAIX_HUMAN 657982 K2C1_HUMAN 66170 K2C1_HUMAN 66170 K1C10_HUMAN 61187 K1C10_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 59020 MPCP_HUMAN 50525 VIME_HUMAN 50366 NPCP_HUMAN 3356 MPCP_HUMAN 33576 NPCP_HUMAN 33576 Stass 33707 Stass 33376 CIQBP_HUMAN 3576 Stass NPM_MAN 35726 Stass Stass Stass NPM_MAN 33707 Stass Stass		BIP_HUMAN	72402	Endoplasmic reticulum chaperone BiP	HSP7C_HUMAN	71082	Heat shock cognate 71 kDa protein
CALX_HUMAN 67982 KZCL_HUMAN 66170 KZCL_HUMAN 66170 CH60_HUMAN 66170 KLCL0_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 59020 MPCP_HUMAN 5675 VIME_HUMAN 50788 MPCP_HUMAN 33576 NPCP_HUMAN 33576 NPCP_HUMAN 33576 NDHM_HUMAN 33576 NDHM_HUMAN 33576 NDHM_HUMAN 33507 JOUR 33507 ORO NPMAN 35766 NPLMAN 33707 JOB NPM_HUMAN 33707 Stass Stass Stass NDM_HUMAN 33707 Stass Stass Stass Cotein NPM_HUMAN 27578 Stass Stass Stass Stass NPM_HUMAN 27578 Stass		CALX_HUMAN	67982	Calnexin	H90B3_HUMAN	68624	Putative heat shock protein HSP 90-beta-3
K2C1_HUMAN 66170 CH60_HUMAN 66170 CH60_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 56525 VIME_HUMAN 56525 VIME_HUMAN 56525 NPCP_HUMAN 56525 NPCP_HUMAN 36525 NPCP_HUMAN 35368 ROA1_HUMAN 35358 NPCP_HUMAN 35358 ROA1_HUMAN 35358 NDHM_HUMAN 35767 Bog NPLMAN 35766 NDHM_HUMAN 35726 NPM_HUMAN 35726 CIQBP_HUMAN 31742 Stssp_HUMAN 31742 scotein 210 NPM_HUMAN 27578 Stssp_HUMAN 27578 Stssp_HUMAN 27578 Stssp_HUMAN 27578 Stssp_HUMAN 27578 Stssp_HUMAN 27578 Stssp_HUMAN 19546 Stssp_HUMAN 18226 <					CALX_HUMAN	67982	Calnexin
CH60_HUMAN 61187 K1C10_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 59020 ATPB_HUMAN 5955 VIME_HUMAN 5655 VIME_HUMAN 5655 NPCP_HUMAN 5655 NPCP_HUMAN 5655 NPCP_HUMAN 3363 ROA1_HUMAN 38837 NPCP_HUMAN 38358 ROA1_HUMAN 37464 G3P_HUMAN 37366 NDHM_HUMAN 37367 NDHM_HUMAN 35766 NDHM_HUMAN 35766 NPR_LHUMAN 35766 NPR_LHUMAN 35766 NPR_LHUMAN 35766 NPM_HMAN 35766 NPM_MAN 32726 Stssr 33774 Stssr 33774 Stssr 33774 Stssr NPM_MAN Stssr 33746 Stssr Stssr Stssr Stssr Stssr Stssr		K2C1_HUMAN	66170	Keratin, type II cytoskeletal 1	K2C1_HUMAN	66170	Keratin, type II cytoskeletal 1
KICI0_HUMAN 59020 ATPB_HUMAN 56555 VIME_HUMAN 56555 VIME_HUMAN 56555 VIME_HUMAN 56555 NPCP_HUMAN 56555 NPCP_HUMAN 56525 NPCP_HUMAN 33566 NPCP_HUMAN 33536 ROA1_HUMAN 38837 NDHM_HUMAN 38837 S000 37464 G3P_HUMAN 35766 NDHM_HUMAN 35301 NDHM_HUMAN 35307 Jog NPM_HUMAN 35726 NPM_HUMAN 33707 S000 NPM_HUMAN 33707 S001 NPM_HUMAN 31742 scenta 32726 NOR_LHUMAN 31742 S001 S001 S002 NPM_HUMAN 22345 S01 SSS7_HUMAN 27578 S00M_HUMAN 27578 S00M_HUMAN 27578 S00M_HUMAN 27578 S00M_HUMAN 27578 S104 NDKB_HUMAN S105 NDKB_H		K1C9_HUMAN	62255	Keratin, type I cytoskeletal 9	CH60_HUMAN	61187	60 kDa heat shock protein, mitochondrial
ATPB_HUMAN 56525 VIME_HUMAN 53676 TBAIA_HUMAN 53676 MPCP_HUMAN 53676 MPCP_HUMAN 50788 MPCU_HUMAN 3353 ROA1_HUMAN 3353 ROA1_HUMAN 3837 NDHM_HUMAN 3353 NDHM_HUMAN 3353 Sign 37464 C3P_HUMAN 33370 MDHM_HUMAN 33370 MDHM_HUMAN 33370 NPM_HUMAN 33370 NPM_HUMAN 33707 Stap NPM_HUMAN 33707 NPM_HUMAN 33707 Stap NPM_HUMAN 31742 scotein 32726 cotein 32726 Stap NPM_HUMAN 23726 Stap NPM_HUMAN 31742 Stap NPM_HUMAN 32726 Stap NPM_HUMAN 32726 Stap NPM_HUMAN 23245 Stap NPMAN 27578 Stap NDKB_HUMAN 27578 Stap		ATPA_HUMAN	59828	ATP synthase subunit alpha, mitochondrial	K1C10_HUMAN	59020	Keratin, type I cytoskeletal 10
VIME_HUMAN 53676 TBAIA_HUMAN 53676 MPCP_HUMAN 50788 MPCU_HUMAN 40525 ROA1_HUMAN 3837 ROA1_HUMAN 3837 ROA1_HUMAN 3837 ROA2_HUMAN 3837 MDHM_HUMAN 38358 ROA2_HUMAN 38370 MDHM_HUMAN 33307 MDHM_HUMAN 35301 MDHM_HUMAN 35307 Jog NPM_HUMAN 35726 NPM_HUMAN 32726 CIQBP_HUMAN 31742 scotein 32726 cotein 32726 cotein 32726 StSF7_HUMAN 32726 StSF7_HUMAN 27578 StSF7_HUMAN 27465 <td></td> <td>ATPB_HUMAN</td> <td>56525</td> <td>ATP synthase subunit beta, mitochondrial</td> <td>ATPB_HUMAN</td> <td>56525</td> <td>ATP synthase subunit beta, mitochondrial</td>		ATPB_HUMAN	56525	ATP synthase subunit beta, mitochondrial	ATPB_HUMAN	56525	ATP synthase subunit beta, mitochondrial
IBAIA_HUMAN 50788 MPCP_HUMAN 40525 MPCP_HUMAN 3837 ROAI_HUMAN 3837 ROAI_HUMAN 38363 ROAI_HUMAN 38364 G3P_HUMAN 37464 G3P_HUMAN 37307 Jog NPM_HUMAN 35937 HNRPC_HUMAN 35937 HNRPC_HUMAN 35937 INPM_HUMAN 35937 NPM_HUMAN 32726 CIQBP_HUMAN 31742 scotein 31742 cotein 31742 scotein 25758 scotein 25758 scotein 25758 scotein 27578 scotein 27578 scotein 27578 scotein		VIME_HUMAN	53676	Vimentin	VIME_HUMAN	53676	Vimentin
MPCP_HUMAN 40525 In TCP10_HUMAN 3837 ROA1_HUMAN 3837 ROA2_HUMAN 3836 ROA2_HUMAN 3836 ROA2_HUMAN 3836 ROA2_HUMAN 3836 NDHM_HUMAN 35201 MDHM_HUMAN 3576 Jog NPM_HUMAN 35726 CIQBP_HUMAN 32726 CIQBP_HUMAN 31742 score 2000		TBA1A_HUMAN	50788	Tubulin alpha-1A chain	TBA1A_HUMAN	50788	Tubulin alpha-1A chain
In TCP10_HUMAN 38837 TCP10_HUMAN 38837 ROA2_HUMAN 37464 G3P_HUMAN 35201 MDHM_HUMAN 35937 HNRPC_HUMAN 33707 S226 CIQBP_HUMAN 31742 ss crein cotein cotein SSF7_HUMAN 28017 SRSF7_HUMAN 19546 RS27A_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 17403 H4_HUMAN 11360		SQOR_HUMAN	50214	Sulfide: quinone oxidoreductase, mitochondrial	MPCP_HUMAN	40525	Phosphate carrier protein, mitochondrial
In TCP10_HUMAN 38358 ROA2_HUMAN 37464 G3P_HUMAN 35201 MDHM_HUMAN 35937 HNRPC_HUMAN 33507 NPM_HUMAN 33707 S2726 CIQBP_HUMAN 31742 s critin critin critin RSF7_HUMAN 28017 SRSF7_HUMAN 28017 SRSF7_HUMAN 28017 SRSF7_HUMAN 28017 SRSF7_HUMAN 28017 SRSF7_HUMAN 28017 SRSF7_HUMAN 28017 SRSF7_HUMAN 28017 SRSF7_HUMAN 28017 SRSF7_HUMAN 19546 PPIA_HUMAN 19546 PPIA_HUMAN 19546 PPIA_HUMAN 18229 NDKB_HUMAN 17403 H4_HUMAN 11360		ACTB_HUMAN	42052	Actin, cytoplasmic 1	ROA1_HUMAN	38837	Heterogeneous nuclear ribonucleoprotein A1
ROA2_HUMAN 37464 G3P_HUMAN 35201 MDHM_HUMAN 35937 hNRPC_HUMAN 35937 hNRPC_HUMAN 35937 hNRPC_HUMAN 35726 NPM_HUMAN 32726 Sign NPM_HUMAN Sign 31742 s CIQBP_HUMAN Sign Sign NPM_HUMAN 28017 ss Stab cotein 27578 scob 27578 SissF7_HUMAN 28017 SissF7_HUMAN 23345 SissF3_HUMAN 23345 SissF3_HUMAN 22345 SissF3_HUMAN 19546 PPIA_HUMAN 18226 NDKB_HUMAN 18229 NDKB_HUMAN 11360			41181	HLA class I histocompatibility antigen, A-2 alpha chain	TCP10_HUMAN	38358	T-complex protein 10A homolog
G3P_HUMAN 36201 MDHM_HUMAN 35937 MDHM_HUMAN 35937 hNRPC_HUMAN 35937 blog NPM_HUMAN 32726 Scontem 32726 clQBP_HUMAN 32726 scontem 31742 scontem 2726 scontem 2726 scontem 2726 scontem 28017 scontem 27578 scontem 27576 scontem 2757	II.		41136	HLA class I histocompatibility antigen, C alpha chain	ROA2 HUMAN	37464	Heterogeneous nuclear ribonucleoproteins A2/B1
MDHM_HUMAN 35937 hNRPC_HUMAN 33707 blog NPM_HUMAN 32726 S CIQBP_HUMAN 31742 s CIQBP_HUMAN 31742 s SSSFT 31742 s PRDX3_HUMAN 28017 sctin ZSSFT_HUMAN 28017 scsSFT_HUMAN 27578 scsSFT_HUMAN 23345 scsSFT_HUMAN 18226 NCALD_HUMAN 18226 scsSFT_HUMAN 182296 PPIA_HUMAN 182296 PPIA_HUMAN 182296 PPIA_HUMAN 17403 H4_HUMAN 11360	noi		41100	HLA class I histocompatibility antigen, A alpha chain	G3P_HUMAN	36201	Glyceraldehyde-3-phosphate dehydrogenase
blog NPM_HUMAN 33707 blog NPM_HUMAN 32726 CIQBP_HUMAN 31742 srtin 25758 SrSF7_HUMAN 28017 SrSF7_HUMAN 28017 SrSF7_HUMAN 24906 NCALD_HUMAN 22345 SODM_HUMAN 22345 SrSF3_HUMAN 19546 PPIA_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 17403 H4_HUMAN 11360	ვაგ		40525	Phosphate carrier protein, mitochondrial	MDHM_HUMAN	35937	Malate dehydrogenase, mitochondrial
blog NPM_HUMAN 32726 clQBP_HUMAN 31742 s s cotein 31742 s s s s cotein 27578 SRSF7_HUMAN 28017 SRSF7_HUMAN 28017 SRSF7_HUMAN 24906 NCALD_HUMAN 24906 NCALD_HUMAN 19546 SRSF3_HUMAN 19296 PPIA_HUMAN 18229 RS27A_HUMAN 18229 NDKB_HUMAN 18229 PPIA_HUMAN 18229 PPIA_HUMAN 18229 PPIA_HUMAN 18229 PPIA_HUMAN 18229 PPIA_HUMAN 18229 PPIA_HUMAN 18229 H4_HUMAN 11360	[38624	Stomatin-like protein 2, mitochondrial	HNRPC_HUMAN	33707	Heterogeneous nuclear ribonucleoproteins C1/C2
s CIQBP_HUMAN 31742 otein 31742 31742 otein 28017 28017 SRSF7_HUMAN 28017 28017 SRSF7_HUMAN 28017 2345 SCDM_HUMAN 23345 23345 SRSF3_HUMAN 19546 23345 SRSF3_HUMAN 18226 28274 NCALD_HUMAN 18226 23345 SRSF3_HUMAN 18226 2345 NDKB_HUMAN 18226 2345 PPIA_HUMAN 18226 17403 H4_HUMAN 11360 11360		TOM40_HUMAN	38211	Mitochondrial import receptor subunit TOM40 homolog	NPM_HUMAN	32726	Nucleophosmin
s otein PRDX3_HUMAN 28017 SRSF7_HUMAN 28017 SRSF7_HUMAN 24906 SODM_HUMAN 24906 NCALD_HUMAN 24906 NCALD_HUMAN 19546 RS27A_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18229 NDKB_HUMAN 17403 H4_HUMAN 11360		CY1_HUMAN	35741	Cytochrome c1, heme protein, mitochondrial	CIQBP_HUMAN	31742	Complement component 1Q subcomponent-binding
otein PRDX3_HUMAN 28017 SRSF7_HUMAN 28017 SRSF7_HUMAN 24906 SODM_HUMAN 24906 NCALD_HUMAN 24906 NCALD_HUMAN 19546 SRSF3_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18229 NDKB_HUMAN 17403 H4_HUMAN 11360		NB5R3_HUMAN	34441	NADH-cytochrome b5 reductase 3 OS=Homo sapiens			protein
otein PRDX3_HUMAN 28017 SRSF7_HUMAN 28017 SRSF7_HUMAN 24906 NCALD_HUMAN 24906 NCALD_HUMAN 19546 RSSF3_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18229 NDKB_HUMAN 17403 H4_HUMAN 11360		PHB2_HUMAN	33276	Prohibitin-2 OS=Homo sapiens			
otein PRDX3_HUMAN 28017 SRSF7_HUMAN 28017 SRSF7_HUMAN 24906 NCALD_HUMAN 24906 NCALD_HUMAN 19546 RS27A_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18229 NDKB_HUMAN 17403 H4_HUMAN 11360		VDAC2_HUMAN	32060	Voltage-dependent anion-selective channel protein 2			
PRDX3_HUMAN 28017 SRSF7_HUMAN 28017 SRSF7_HUMAN 27578 SODM_HUMAN 24906 NCALD_HUMAN 24906 NCALD_HUMAN 24906 SRSF3_HUMAN 19546 SRSF3_HUMAN 18296 PPIA_HUMAN 18226 PPIA_HUMAN 18229 H4_HUMAN 11360		CIQBP_HUMAN	31742	Complement component 1Q subcomponent-binding protein			
PRDX3_HUMAN 28017 SRSF7_HUMAN 27578 SRSF7_HUMAN 27578 SODM_HUMAN 24906 NCALD_HUMAN 24906 NCALD_HUMAN 23345 SRSF3_HUMAN 19546 SRSF3_HUMAN 18296 PPIA_HUMAN 18229 NDKB_HUMAN 17403 H4_HUMAN 11360		VDAC1_HUMAN	30868	pendent			
PRDX3_HUMAN 28017 SRSF7_HUMAN 27578 SRSF7_HUMAN 27578 SODM_HUMAN 24906 NCALD_HUMAN 24906 NCALD_HUMAN 23345 SRSF3_HUMAN 19546 RS27A_HUMAN 18296 PPIA_HUMAN 18229 NDKB_HUMAN 17403 H4_HUMAN 11360		PHB_HUMAN	29843	Prohibitin			
SKSF7_HUMAN 27578 SODM_HUMAN 24906 NCALD_HUMAN 24906 NCALD_HUMAN 24906 SRSF3_HUMAN 19546 RS27A_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18296 PPIA_HUMAN 18229 H4_HUMAN 11360		PRDX3_HUMAN	28017	Thioredoxin-dependent peroxide reductase	PRDX3_HUMAN	28017	Thioredoxin-dependent peroxide reductase
SODM_HUMAN 24906 NCALD_HUMAN 24906 NCALD_HUMAN 22345 SRSF3_HUMAN 19546 RS27A_HUMAN 18296 PPIA_HUMAN 18296 PDIA_HUMAN 18229 NDKB_HUMAN 17403 H4_HUMAN 11360		COX2_HUMAN	61/52	Cytochrome c oxidase subunit 2	SKSF/_HUMAN	8/9/7	Serine/arginine-rich splicing factor /
NCALD_HUMAN 22345 SRSF3_HUMAN 19546 RS27A_HUMAN 18296 PPIA_HUMAN 18229 NDKB_HUMAN 17403 H4_HUMAN 11360	.I		24492	Ras-related protein Rab-11A	SODM_HUMAN	24906	Superoxide dismutase [Mn]
SRSF3_HUMAN 19546 RS27A_HUMAN 18296 PPIA_HUMAN 18229 NDKB_HUMAN 17403 H4_HUMAN 11360	Πι		23760	Ras-related protein Rab-7a	NCALD_HUMAN	22345	Neurocalcin-delta
RS27A_HUMAN 18296 PPIA_HUMAN 18229 NDKB_HUMAN 17403 H4_HUMAN 11360	1015		19546	Serine/arginine-rich splicing factor 3	SRSF3_HUMAN	19546	Serine/arginine-rich splicing factor 3
PPIA_HUMAN 18229 NDKB_HUMAN 17403 H4_HUMAN 11360	ЗэЯ		14225	Histone H2A type 1-A	RS27A_HUMAN	18296	Ubiquitin-40S ribosomal protein S27a
NDKB_HUMAN 17403 H4_HUMAN 11360		H4_HUMAN	11360	Histone H4	PPIA_HUMAN	18229	Peptidyl-prolyl cis-trans isomerase A
					NDKB_HUMAN H4_HUMAN	17403 11360	Nucleoside diphosphate kinase B Histone H4
	Sele	scted important prote	ins are list	ed on the SDS gel and are shown in bold in the table.			

			MEMBRANE FRACTION		CY	CYTOPLASMIC FRACTION
	Accession	Mass (Da)	Mass (Da) Description	Accession	Mass (Da)	Mass(Da) Description
	PRR36_HUMAN	132748	Proline-rich protein 36	ENPL_HUMAN	92469	Endoplasmin
.I n	ITA2_HUMAN	129925	Integrin alpha-2	MTSS2_HUMAN	80460	Protein MTSS 2
ioig	GANAB_HUMAN	107263	Neutral alpha-glucosidase AB	CALX_HUMAN	06629	Calnexin
Reg	CD44_HUMAN	82009	CD44 antigen			
	CALX_HUMAN	67990	Calnexin			
	5NTD_HUMAN	63908	5'-nucleotidase	K2C1_HUMAN	66173	Keratin, type II cytoskeletal 1
	VIME_HUMAN	53677	Vimentin	MED26_HUMAN 65446	65446	Mediator of RNA polymerase II transcription
						subunit 26
	TBA1A_HUMAN	50800	Tubulin alpha-1A chain	EIF2D_HUMAN	65304	Eukaryotic translation initiation factor 2D
	ACTB_HUMAN	42058	Actin, cytoplasmic 1	K2C1B_HUMAN	62154	Keratin, type II cytoskeletal 1b
Πι	PHB2_HUMAN	33276	Prohibitin-2	KIC10_HUMAN	59024	Keratin, type I cytoskeletal 10
1015	VDAC2_HUMAN	32069	Voltage-dependent anion-selective protein 2	VIME_HUMAN	53677	Vimentin
3əY	PHB_HUMAN	29804	Prohibitin	TBA1A_HUMAN	50800	Tubulin alpha-1A chain
[KPSH2_HUMAN	43027	Serine/threonine-protein kinase H2
				ROA1_HUMAN	38837	Heterogeneous nuclear ribonucleoprotein A1
				ROA2_HUMAN	38542	Heterogeneous nuclear ribonucleoproteins A2/B1
				G3P_HUMAN	36201	Glyceraldehyde-3-phosphate dehydrogenase
				HNRPC_HUMAN	33708	Heterogeneous nuclear ribonucleoproteins C1/C2
	PRDX3_HUMAN 27693	27693	Thioredoxin-dependent peroxide reductase	SODM_HUMAN	24906	Superoxide dismutase [Mn], mitochondrial
.II	COX2_HUMAN	25722	Cytochrome c oxidase subunit 2	CALL3_HUMAN	16891	Calmodulin-like protein 3
Iu	RAB5C_HUMAN	23696	Ras-related protein Rab-5C	H2A1A_HUMAN	14225	Histone H2A type 1-A
Dige	RAB7A_HUMAN 23490	23490	Ras-related protein Rab-7a	H2B1B_HUMAN	13950	Histone H2B type 1-B
Ъ	H2A1A_HUMAN	14225	Histone H2A type 1-A	H4_HUMAN	11360	Histone H4
	H4_HUMAN	11360	Histone H4			
Sel	ected important prot	eins are list	Selected important proteins are listed on the SDS gel and are shown in bold in the table.			

Table 2. Summary of identified proteins found after ATRA treatment in individual cell fraction

rence of which may explain its ability to form a dimer and possible modifications (Qin and Buehler 2010).

For deeper analysis, the obtained 1D maps were processed by PDQuest software[™] and compared with a focus on quantitative and qualitative changes. The changes were monitored in the control samples and the samples after treatment. The comparative data were obtained from three independent replicates from each sample (control and ATRA treated) where the chosen spots were used for the pairwise comparisons of relative protein amount. The quantification of chosen proteins in spots was then expressed as the sum of pixel intensities in a given spot. To eliminate some of the image differences caused by the gel staining and de-staining process, the normalization between individual gel images was performed. Obtained data based on PDQuest software analyses were presented as mean \pm SD (standard deviation) from three independent experiments. Statistical analyses were performed with Student's t-test. Differences between more than two groups were assessed by one-way analysis of variance (ANOVA) followed by the Student Newman-Keuls method. Differences with p < 0.05 were considered as statistically significant.

Based on the results obtained, the identified proteins were compared according to their expression influenced by ATRA. Significant effects were seen mainly in VIME as well as in its HMW form, where the protein levels in the membrane and cytoplasmic fraction were almost completely suppressed after treatment with ATRA (see Fig. 2).

The reduction effects of ATRA were also visible in cases of CD44. The obtained PDQuest data report the most significant decrease of cytoplasmic CD44 level for treatment by the




Figure 2. Graph expression of VIME and CD44 representation after treatment with ATRA. The level of proteins found in individual cell fractions was evaluated according to gel electrophoresis separation and subsequent PDQuest software analyses. The quantitative representation of proteins was based on automated spot matching algorithm and normalization between individual pair gels. Each bar represented the means ± SD of three separate experiments. * *p* < 0.05, ** *p* < 0.01 and *** *p* < 0.001 compared to control sample.

ATRA, where the amount of protein was almost impossible to identify. However, this finding does not correspond to the results obtained with membrane CD44 of which concentration was decreased only partially (Fig. 2).

Recently, several types of treatment with ATRA were carried out on the cell lysis of human triple-negative MDA-MB-231 cells. ATRA, 9-cis retinoic acid, and a mixture of these two retinoic receptor ligands were tested by Flodrova et al. (2017). The treatment of MDA-MB-231 cells with triorganotin compounds together with ATRA resulted in an additional reduction of annexin 5, nucleoside diphosphate kinase B and VIME (Strouhalova et al. 2019, 2020). In this work, the hypothesis of these studies which stated that ATRA led to a significant reduction in VIME as well as CD44 protein level was confirmed. Moreover, our findings verified that although alternative splicing can produce a large number of different isoforms of CD44, they all retain a common transmembrane and cytoplasmic domain (Thorne et al. 2004) and therefore it is important to study its presence in both the membrane and cytoplasmic fractions obtained by sequential protein extraction.

In conclusion, this work provides first insights into the presentation of VIME and CD44 in the cytoplasmic and membrane protein fraction in the MDA-MB-231 cells after ATRA treatment. Some types of cancer can become more invasive and malignant after undergoing the EMT process. VIME is one of the types of protein markers of EMT that is present in mesenchymal cells and is involved in cancer progression (Kalluri and Weinberg 2009; Zeisberg and Neilson 2009). Also, some findings suggest that CD44 may provide some growth benefits to some neoplastic cells and therefore could be used as a cancer treatment target (Naor et al. 1997). We are convinced that the present data can help reveal additional aspects of the mechanism of action of all-*trans* retinoic acid in breast cancer, which we consider a highly desirable.

Acknowledgements. The present study was supported by institutional support RVO:68081715 of the Institute of Analytical Chemistry of the CAS, SAV-18-16, APVV-15-0372 and VEGA2/0171/17 grants.

References

- Ahrens T, Sleeman JP, Schempp CM, Howells N, Hofmann M, Ponta H, Herrlich P, Simon JC (2001): Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene **20**, 3399-3408 https://doi.org/10.1038/sj.onc.1204435
- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003): Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983-3988 https://doi.org/10.1073/pnas.0530291100

Alizadeh F, Bolhassani A, Khavari A, Bathaie SZ, Naji T, Bidgoli SA (2014): Retinoids and their biological effects against cancer. Int. Immunopharmacol. **18**, 43-49

https://doi.org/10.1016/j.intimp.2013.10.027

- Bordier C (1981): Phase-separation of integral membrane-proteins in triton X-114 solution. J. Biol. Chem. **256**, 1604-1607
- Carlberg C, Saurat JH, Siegenthaler G (1993): 9-cis-retinoic acid is a natural antagonist for the retinoic acid receptor response pathway. Biochem. J. **295**, 343-346 https://doi.org/10.1042/bj2950343
- Chen Ch, Zhao S, Karnad A, Freeman JW (2018): The biology and role of CD44 in cancer progression: therapeutic implications. J. Hematol. Oncol. **11**, 64
- https://doi.org/10.1186/s13045-018-0605-5 Chen MC, Hsu SL, Lin H, Yang TY (2014): Retinoic acid and cancer treatment. Biomedicine (Taipei) **4**, 22

https://doi.org/10.7603/s40681-014-0022-1

- Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005): Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. **65**, 10946-10951 https://doi.org/10.1158/0008-5472.CAN-05-2018
- Dalerba P, Dylla SJ, Park I-K, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al. (2007): Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA **104**, 10158-10163 https://doi.org/10.1073/pnas.0703478104
- Eibl RH, Pietsch T, Moll J, Skroch-Angel P, Heider K-H, von Ammon K, Wiestler OD, Ponta H, Kleihues P, Herrlich P (1995): Expression of variant CD44 epitopes in human astrocytic brain tumors. J. Neurooncol. 26, 165-170 https://doi.org/10.1007/BF01052619
- Flodrova D, Benkovska D, Macejova D, Bialesova L, Hunakova L, Brtko J, Bobalova J (2015): Proteomic analysis of changes in the protein composition of MCF-7 human breast cancer cells induced by all-trans retinoic acid, 9-cis retinoic acid, and their combination. Toxicol. Lett. **232**, 226-232 https://doi.org/10.1016/j.toxlet.2014.09.030
- Flodrova D, Toporova L, Lastovickova M, Macejova D, Hunakova L, Brtko J, Bobalova J (2017): Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: focus on functional proteomics. Toxicol. Lett. 281, 26-34

https://doi.org/10.1016/j.toxlet.2017.09.001

- Kalluri R, Weinberg RA (2009): The basics of epithelial-mesenchymal transition. J. Clin. Invest. **119**, 1420-1428 https://doi.org/10.1172/JCI39104
- Li CW, Heidt DG, Dalerba P, Burant CF, Zhang LJ Asday V, Wicha M, Clarke MF, Simeone DM (2007): Identification of pancreatic cancer stem cells. Cancer Res. **67**, 1030-1037 https://doi.org/10.1158/0008-5472.CAN-06-2030

Naor D, Sionov RV, IshShalom D (1997): CD44: Structure, function, and association with the malignant process. Adv. Cancer Res. **71**, 241-319

https://doi.org/10.1016/S0065-230X(08)60101-3

- _ _ . .
- Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y (2002): CD44 in cancer. Crit. Rev. Clin. Lab. Sci. **39**, 527-579 https://doi.org/10.1080/10408360290795574
- Neagu M, Constantin C, Bostan M, Caruntu C, Ignat SR, Dinescu S, Costache M (2019): Technology "Lens" for epithelial-mesenchymal transition process identification in oncology. Anal. Cell Pathol. 2019, 3565970 https://doi.org/10.1155/2019/3565970

Qin Z, Buehler MJ (2010): Structure and dynamics of human vimentin intermediate filament dimer and tetramer in explicit and implicit solvent models. J. Mol. Model. **17**, 37-48 https://doi.org/10.1007/s00894-010-0696-6

- Santoni V, Molloy M, Rabilloud T (2000a): Membrane proteins and proteomics: Un amour impossible? Electrophoresis **21**, 1054-1070 https://doi.org/10.1002/(SICI)1522-2683(20000401)21:6<1054::A-ID-ELPS1054>3.0.CO;2-8
- Santoni V, Kieffer S, Desclaux D, Masson F, Rabilloud T (2000b): Membrane proteomics: Use of additive main effects with multiplicative interaction model to classify plasma membrane proteins according to their solubility and electrophoretic properties. Electrophoresis **21**, 3329-3344

https://doi.org/10.1002/1522-2683(20001001)21:16<3329::A-ID-ELPS3329>3.0.CO;2-F

Satelli A, Li S (2011): Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci. **68**, 3033-3046

https://doi.org/10.1007/s00018-011-0735-1

- Shi G, Zheng X, Wu X, Wang S, Wang Y, Xing F (2019): All-trans retinoic acid reverses epithelial-mesenchymal transition in paclitaxel-resistant cells by inhibiting nuclear factor kappa B and upregulating gap junctions. Cancer Sci. **110**, 379-388 https://doi.org/10.1111/cas.13855
- Strouhalova D, Toporova L, Lastovickova M, Macejova D, Bobalova J, Brtko J (2019): Novel insights into the combined effect of triorganotin compounds and all-trans retinoic acid on expression of selected proteins associated with tumor progression in breast cancer cell line MDA-MB-231: proteomic approach. Gen. Physiol. Biophys. 38, 135-144 https://doi.org/10.4149/gpb_2018042
- Strouhalova D, Macejova D, Mosna B, Bobal P, Otevrel J, Lastovickova M, Brtko J, Bobalova J (2020): Down-regulation of vimentin by triorganotin isothiocyanates-nuclear retinoid X receptor agonists: A proteomic approach. Toxicol. Lett. **318**, 22-29 https://doi.org/10.1016/j.toxlet.2019.10.004
- Thorne RF, Legg JW, Isacke CM (2004): The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. J. Cell Sci. **117**, 373-380 https://doi.org/10.1242/jcs.00954
- Zeisberg M, Neilson EG (2009): Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. **119**, 1429-1437 https://doi.org/10.1172/JCI36183

Received: May 18, 2020 Final version accepted: July 7, 2020